Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.

C PaulL GuentherH ToriiHoward SofenR BurgeC Y LinA Potts BleakmanL MallbrisY Poulin

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2017)

Facial psoriasis had a larger negative impact on HRQoL than no facial psoriasis. Facial psoriasis clearance was associated with improved HRQoL. Significantly more IXE-treated patients had rapid facial clearance vs. ETN and PBO, which led to better clinical outcomes.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
phase iii
soft tissue
clinical trial
prognostic factors
atopic dermatitis
early onset
randomized controlled trial
patient reported outcomes
quantum dots